Synexus India said it will run the two Phase III studies on a cardiac drug from its new centre in Mumbai, on behalf of a top five pharmaceutical firm.
The company, which specialises in the recruitment and running of late stage clinical trials, said it also expects to announce further study contracts shortly.
India is now holding the lion's share of the world's contract research business as activity in the pharma market continues to explode in this region and offer low-cost competition with the West.
As a result, over 15 prominent contract research organisations (CROs), and over ten large multinational pharma companies are now already operating in the country, and many who are not yet established in the region, such as Synexus have been scrambling to get their foot in the door.
Synexus has also been expanding its presence in Eastern Europe, another growth market for clinical research, with recent acquisitions in Hungary, Poland and the opening of an office in Bulgaria.
"Further geographic expansion is now planned both in existing and in new countries," said the firm.
